This page is updated thanks to the FFund team. Last update: Dec 5,, 2022. If any question, please contact Lorina Gjonaj, Senior Consultant – M +316 347 340 00 | lorina.gjonai@ffund.nl or Maarten Korving, Consultant, M +316 393 425 26 | maarten.korving@ffund.nl.
General non-dilutive instruments
Eurostars-3
Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union. It aims to bring increased value to the economy, higher growth and more job opportunities. Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world. Eurostars has been carefully developed to meet the specific needs of SMEs. It is an ideal first step in international cooperation, enabling small businesses to combine and share expertise and benefit from working beyond national borders.
Funding Name: Eurostars
Funding Organization: Eureka
Amount of funding per project: €500K per partner (varies per country)
Funding versus total project costs: 35-45% of total project costs (varies per country)
Funding type: Subsidy
Close date: 2 deadlines/year (March 9, 2023 and September 2023 – specific date still unknown)
Duration of eligible projects: 36 months
Evaluation results expected: May 2023
Scope and Eligibility criteria:
– Programme supporting R&D performing SMEs and their partners
– The development of new products, processes, and services
– The budget (excluding subcontracting) of the R&D-performing SME is equal to at least 50.00% of the total project budget
– At least 2 different partners from 2 different Eurostars countries
– No organization can be responsible for more than 75% of the total project budget.
– No participants from a given country may be responsible for more than 75% of the total project budget
– The project must be completed in 36M or fewer and the market introduction (or the start of clinical trials for life sciences projects) is planned to occur within 24M of the project’s completion
– Two application submission deadlines annually
To qualify as an R&D-performing SME, an organization must first comply with the EC definition of an SME. In addition, it must also meet the thresholds for dedicated R&D FTEs or turnover set by EUREKA.This and all other eligibility criteria are described in detail in the Guidelines. An explanation of the eligibility criteria imposed by the programme and the method of calculation are provided in detail in the Eligibility Guidelines.
Procedure and application process: For more information click here.
EIC PATHFINDER OPEN
The overall objective of the EIC Pathfinder for advanced research is to develop the scientific basis to underpin breakthrough technologies. It provides support for the earliest stages of scientific, technological or deep-tech research and development. Pathfinder projects aim to build on new, cutting-edge directions in science and technology to disrupt a field and a market or create new opportunities by realizing innovative technological solutions through:
EIC Pathfinder Open’, open to support projects in any field of science, technology or application without predefined thematic priorities.
Funding Name: EIC Pathfinder
Funding Organization: European Commission
Amount of funding per project: Up to €4M (total budget €179M)
Funding versus total project costs: 100% of eligible costs
Close date: March 7, 2023
Duration of eligible projects: 3 years
Evaluation results expected: 5 months
Scope: You should apply if you are looking for support from EIC Pathfinder Open to realise an ambitious vision for radically new technology, with potential to create new markets and/or to address global challenges. EIC Pathfinder Open supports early stage development of such future technologies (e.g. various activities at low Technology Readiness Levels 1-4), based on high-risk/high-gain science-towards-technology breakthrough research (including ‘deep-tech’). This research must provide the foundations of the technology you are envisioning.
Before applying to this call, you should verify that your proposal meets all the following essential characteristics (‘Gatekeepers’):
• Convincing long-term vision of a radically new technology that has the potential to have a transformative positive effect to our economy and society;
• Concrete, novel and ambitious science-towards-technology breakthrough, providing advancement towards the envisioned technology;
• High-risk/high-gain research approach and methodology, with concrete and plausible objectives.
Eligibility criteria: This call is open for collaborative research. Your proposal must be submitted by the coordinator, on behalf of a consortium including as beneficiaries, at least three legal entities, independent from each other and each established in a different country as follows:
• at least one legal entity established in a Member State; and
• at least two other independent legal entities, each established in different Member States or Associated Countries.
The legal entities may for example be universities, research organisations, SMEs, startups, industrial partners or natural persons.
Procedure and application process: For more information, click here.
EIC Accelerator OPEN
The EIC Accelerator supports high-risk, high-potential small and medium-sized enterprises and innovators to help them develop and bring onto the market new innovative products, services and business models that could drive economic growth. Selected companies receive funding and optional equity, and are offered business coaching and mentoring services to scale up their innovation idea. In addition, they receive acceleration services to connect with investors, corporates and likeminded entrepreneurs.
Funding Name: EIC Accelerator
Funding Organization: European Commission
Amount of funding per project: € 0.5-2.5M (+€0.5-15M equity)
Funding versus total project costs: 70% of eligible costs (grant part)
Close date: 4 deadlines/year (upcoming call: January 11, March 22, June 7 and October 4, 2023)
Duration of eligible projects: 12-24 months (maximum)
Evaluation results expected: 3-6 weeks later (for 2nd and 3rd phase)
Scope: The EIC Accelerator helps you develop your business concept further into a market-ready product, service or process aligned with your company’s growth strategy. Activities could, for example, include trials, prototyping, validation, demonstration and testing in real-world conditions, and market replication. If the activity concerns a primarily technological innovation, a Technology Readiness Level (TRL) of 6-8 is envisaged for projects requesting grants-only. Projects are able to receive between € 0.5 and € 2.5 million in the form of grants. They can request a higher or lower amount when applying if justified accordingly. Projects should normally take 12 to 24 months to complete but could be longer in exceptional and well-justified cases. Since 5 June 2019 the EIC Accelerator offers blended finance in the form of an optional investment in equity in addition to the grant, to single for-profit SMEs. Grants will finance activities from TRL 6-8. Activities above TRL 8 will be funded through equity. The equity part is optionable when applying for the EIC Accelerator. The maximum of investment in the form of equity is € 15 million.
Eligibility criteria: The EIC Accelerator is designed for small and medium-sized enterprises (SMES) with radically new ideas underpinned by a business plan for rolling out marketable innovation solutions and with ambitions to scale up. It targets for-profit SMEs only, including young companies and start-ups, from any sector – there are no set topics. Since 5 June 2019 only single companies (as opposed to consortia) can apply for EIC Accelerator. Companies that apply must be established in an EU Member State or a Horizon 2020 associated country. Large corporates, research centers or scientists cannot apply directly but they can participate in projects as subcontractors or third parties and don’t need to be established in an EU Member State or associated country.
Procedure and application process: For more information, click here. Please note that short application can be submitted any time.
EIC Accelerator challenge: Aerosol and surface decontamination for pandemic management
The EIC Accelerator supports high-risk, high-potential small and medium-sized enterprises and innovators to help them develop and bring onto the market new innovative products, services and business models that could drive economic growth. Selected companies receive funding and optional equity, and are offered business coaching and mentoring services to scale up their innovation idea. In addition, they receive acceleration services to connect with investors, corporates and likeminded entrepreneurs.
Funding Name: EIC Accelerator (€65M)
Funding Organization: European Commission
Amount of funding per project: € 0.5-2.5M (+€0.5-15M equity)
Funding versus total project costs: 70% of eligible costs (grant part)
Close date: 4 deadlines/year (upcoming call: March 22, June 7 and October 4 2023)
Duration of eligible projects: 12-24 months (maximum)
Evaluation results expected: 3-6 weeks later (for 2nd and 3rd phase)
Scope: The proposals should target the development and commercialisation of technological solutions facilitating social interaction in the context of pandemic emergencies, by means of one or more of the three following approaches:
• Full systems for high-efficiency aerosol capture, pathogen deactivation and air circulation management in closed-environments (e.g., office space, in-flight, retail stores, etc.), including advanced air-filtering architectures and dynamic air circulation optimisation.
• Next-generation face mask technologies with smart filtration materials to exceed N95 performance at low airflow resistance, with improved retention/rejection of sub-micron particles
• Rapid surface decontamination devices beyond state-of-the-art UV-C irradiation systems and biocidal agent dispersion.
By reducing the need for social distancing in the event of infectious pandemics, this Challenge will empower society at large to sustain unaltered economic and social dynamics in the event of pandemic outbreaks.
Eligibility criteria: The EIC Accelerator is designed for small and medium-sized enterprises (SMES) with radically new ideas underpinned by a business plan for rolling out marketable innovation solutions and with ambitions to scale up. It targets for-profit SMEs only, including young companies and start-ups, from any sector – there are no set topics. Since 5 June 2019 only single companies (as opposed to consortia) can apply for EIC Accelerator. Companies that apply must be established in an EU Member State or a Horizon 2020 associated country. Large corporates, research centers or scientists cannot apply directly but they can participate in projects as subcontractors or third parties and don’t need to be established in an EU Member State or associated country.
Procedure and application process: For more information, click here. Please note that short application can be submitted any time.
HORIZON-HLTH-2023-DISEASE-03-04
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
• The scientific and clinical communities have an increased knowledge on viruses with epidemic potential and in particular a better understanding of different potential mechanisms of action for the development of broad-spectrum anti-viral therapeutics for these viruses.
• The scientific and clinical communities have access to novel approaches for the development of anti-viral therapies for emerging and re-emerging infections in the context of epidemic and pandemic preparedness.
• The scientific and clinical communities have access to experimental broad-spectrum anti-viral candidates against emerging or re-emerging viral infections for further clinical investigation.
• A diverse and robust pipeline of broad-spectrum anti-viral drug candidates is available for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Funding Name: Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential (Research and Innovation Action call)
Funding Organization: European Commission
Amount of funding per project: € 7-8M (Total budget €50M)
Funding versus total project costs: 100%
Close date: Opening January 12, 2023 – Closing April 13, 2023
Duration of eligible projects: Typically 4-5 years
Evaluation results expected: Typically 5 months
Scope: As shown by the COVID-19 pandemic, infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is expected to accelerate due to among other, climate change, and thus a proactive approach to the development of anti-viral therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of broad-spectrum anti-viral therapies would provide a critical preparedness measure against future health threats, due to infectious disease epidemics or pandemics.
Eligibility criteria: Proposals should address all of the following areas:
• Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials for testing new or improved anti-viral therapeutics, with a clear regulatory and clinical pathway. Phase IIb/III phase trials will not be supported;
• Innovative delivery systems and suitable safety profiles for broad use should be considered when possible. Attention should be paid to critical social factors such as sex, gender, age, socio-economic factors, ethnicity/migration, and disability;
• Application of novel approaches and widely applicable workflows (e.g. artificial intelligence) for rapid and reliable identification of broad-spectrum anti-viral therapeutics.
Procedure and application process: For more information, click here.
HORIZON-HLTH-2023-DISEASE-03-05
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
• The research community sustains appropriate coordination mechanisms 1) among different EU-wide adaptive platform trials and/or 2) among established cohorts in Europe and beyond with a view for better pandemic preparedness and response;
• The adaptive platform trial and/or the cohort networks maximise coordination and harmonisation of their respective studies within their relevant network for maximum research efficiency and optimal evidence generation;
• The European adaptive platform trial and/or the cohort networks coordinate with the European Pandemic Preparedness Partnership, and are well connected to each other and to relevant other regional and global initiatives.
Funding Name: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks (Coordination and Support Actions call)
Funding Organization: European Commission
Amount of funding per project: € 1-2M (Total budget €3M)
Funding versus total project costs: 100%
Close date: Opening January 12, 2023 – Closing April 13, 2023
Duration of eligible projects: Unspecified
Evaluation results expected: Typically 5 months
Scope: Proposals should describe a coordination mechanism for adaptive platform trials and/or for cohort research. The coordination mechanism builds on existing coordination efforts for these networks, providing strategic support and vision for the perpetual trials and cohort studies belonging to the networks in the context of pandemic preparedness. Within the adaptive platform trial network, the coordination mechanism supports reflections e.g. on the diversity of the trial target populations (e.g. primary care or hospitalised patients) or on different possible medical countermeasures (e.g. therapeutics, vaccines), etc. Within the cohort network, the coordination mechanism supports reflections e.g. on diversity in type of cohorts and research questions to be addressed, or on harmonised approaches to data collection and analysis, etc.
Eligibility criteria: Proposals should address the following areas:
• Fostering a trusted and proactive environment within the coordination mechanism that supports the timely exchange of research results, allows for discussion on challenges encountered in their research and finding solutions together to ensure cooperation and synergy within each network;
• Developing a common approach for the European clinical research to enable pragmatic solutions to shared challenges across European clinical trials and/or cohorts for pandemic preparedness and response, guaranteeing the best interest of European trial or study patients or volunteers;
• Promoting an optimal use of resources, based on a sound scientific approach and maximising the value added for the generation of scientific evidence, through a common baseline approach towards protocol development, harmonised and FAIR data collection and analysis leveraging existing initiatives.
Procedure and application process: For more information, click here.
HORIZON-HLTH-2023-DISEASE-03-07
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to the following expected outcomes:
• All players along the health care value chain are provided with new knowledge for a better understanding of the links (e.g. causalities) between infectious diseases (IDs) and non-communicable diseases (NCDs) and comorbidities, including knowledge on host risk factors that impact the development of disease progression for NCDs and/or IDs;
• Researchers and clinicians are provided with a robust evidence base that will contribute to the development of new or improved tools to diagnose and prevent the development and aggravation of non-communicable disease(s) as well as early treatment and management of patients suffering from co-morbidities following an infectious disease;
• Healthcare practitioners have access to knowledge to guide them on preventive measures, on early identification of diseases onset and of those patients at risk of developing severe disease progression, and on the optimal treatment of patients.
Funding Name: Relationship between infections and non-communicable diseases (Research Innovation Action call)
Funding Organization: European Commission
Amount of funding per project: € 6-7M (Total budget €30M)
Funding versus total project costs: 100%
Close date: Opening January 12, 2023 – Closing April 13, 2023
Duration of eligible projects: Unspecified
Evaluation results expected: Typically 5 months
Scope: Increasing evidence suggests that several infections might influence the development of many non-communicable diseases (e.g. multiple sclerosis, Alzheimer, post-covid-19 condition), or that NCD may be influenced by concurrent presence in the same individual of one (or more) infections. On the other hand, NCDs might represent risk factors for IDs. The proposals are expected to elucidate and provide a better understanding of causative links between infections and non-communicable diseases onsets, and/or the impact of infections on the exacerbation of existing NCDs or vice versa, in children and/or adults. The analysis of genetics, immune status, immune or inflammatory responses, microbiome, lifestyle and/or other relevant factors (e.g. differences in age, sex/gender, vaccination status, ethnicity) should be integrated to get information for prevention, early diagnosis, risk factors, and to better understand causative links as well as the progression of those non-communicable diseases.
Eligibility criteria: Preclinical research, observational studies and/or clinical studies can be considered for this topic. Proposals could include patient follow-up to identify conditions that may appear only after a patient has recovered from the infectious disease. Those proposals including clinical evaluation should give a sound feasibility assessment, provide details of the methodology, including an appropriate patient selection and realistic recruitment plans, justified by available publications and/or preliminary results.
The applicants are encouraged to incorporate artificial intelligence (AI) tools that enable advanced quality data analysis and for assessing and predicting the risk of developing a disease and/or the risk of disease progression/severity where relevant.
Procedure and application process: For more information, click here.
HORIZON-HLTH-2023-DISEASE-03-17
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
• The scientific and clinical communities have an increased knowledge of vaccine-induced immunity and, in particular, a better understanding of factors that affect the magnitude, breadth, nature and duration of immunity to vaccine antigens;
• The scientific and clinical communities have an increased knowledge of the durability and breadth of vaccine-induced immunity in vulnerable populations and older age groups;
• The scientific and clinical communities have an increased knowledge of correlates of protection for pathogens with epidemic potential to allow the development of effective vaccines;
• The scientific and clinical communities have an increased knowledge of the characteristics that influence vaccine effectiveness to allow for novel approaches for the development of vaccines for emerging and re-emerging infections, including antigenic variants, in the context of epidemic and pandemic preparedness.
Funding Name: Pandemic preparedness and response: Understanding vaccine induced-immunity (Research and Innovation Action call)
Funding Organization: European Commission
Amount of funding per project: € 7-8 (Total budget €20M)
Funding versus total project costs: 100%
Close date: Opening January 12, 2023 – Closing April 13, 2023
Duration of eligible projects: Unspecified
Evaluation results expected: Typically 5 months
Scope: As shown by the COVID-19 pandemic, vaccines are a critical component needed to bring infectious disease pandemics under control. The availability of effective vaccines that are able to induce a strong and durable immune response are critical to respond to health threats caused by infectious disease epidemics or pandemics. A proactive approach to understanding the factors that affect vaccine durability and strength is necessary to ensure development of effective vaccines for future infectious disease outbreaks.
Eligibility criteria:
• Proposals should study vaccine-induced immunity in the general population and vulnerable groups. Proposals should look both at the magnitude and breadth of initial immune responses and the duration of immunity after vaccination with different vaccine types (mRNA, vector, inactivated, subunit, attenuated,…). Proposals should assess how sex (e.g. male vs female, pre- vs postmenopausal), age (childhood vs adolescent vs elderly) and/or lifestyle (e.g. obesity, drug addiction, diet, sport) affect the immune response. Proposals may also examine genetic and other molecular factors that may influence immune response in humans. Proposals should pursue a multi-omics approach in order to foster a deep understanding of vaccine induced immunity.
• Proposals should identify correlates of protection that can be used to develop vaccines against viruses meeting the criteria for pathogens with high pandemic potential as identified by HERA.
• Proposals should also assess how pre-existing conditions or chronic infections influence the immune response.
Procedure and application process: For more information, click here.
HORIZON-HLTH-2023-DISEASE-03-18
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
• The scientific and clinical communities have an increased knowledge on viruses with epidemic and pandemic potential and in particular a better understanding of viral targets for vaccine development.
• The scientific and clinical communities have access to novel approaches for the prevention and treatment for emerging and re-emerging infections in the context of epidemic and pandemic preparedness.
• The scientific and clinical communities have access to experimental vaccine candidates against emerging or re-emerging viral infections for further clinical investigation.
• A diverse and robust pipeline of vaccine candidates is available for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Funding Name: Pandemic preparedness and response: Immunogenicity of viral proteins of viruses with epidemic and pandemic potential (Research and Innovation Action call)
Funding Organization: European Commission
Amount of funding per project: € 7-8 (Total budget €50M)
Funding versus total project costs: 100%
Close date: Opening January 12, 2023 – Closing April 13, 2023
Duration of eligible projects: Unspecified
Evaluation results expected: Typically 5 months
Scope: As shown by the COVID-19 pandemic, infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is expected to accelerate due to among other factors, climate change, and thus a proactive approach to the development of vaccines and inhibitors for the cellular uptake of viruses in preparedness for future infectious disease outbreaks is needed. The availability of vaccines against pathogens with high pandemic potential meeting the criteria identified by the Health Preparedness and Response Authority (HERA) would provide a critical preparedness measure against future health threats.
Eligibility criteria:
• Proposals should identify targets for optimal vaccine design for those pathogens where information on host-pathogen interaction and viral surface structures is already available. These surface structures may require further characterisation. It is necessary to determine the extent of genetic variation with a view to develop vaccines with variant efficacy.
• Proposals should provide innovative approaches with the aim to diversify and accelerate the global pandemic preparedness research and development pipeline for emerging and re-emerging viral infections, and to strengthen the role of the EU in therapeutic research and development, and therefore contributing to the work of the European Health Emergency Preparedness and Response Authority.
• Proposals should address several of the following areas: Identification of key antigenic targets for the priority pathogens as mentioned above. Improvement or, if necessary, establishment of animal models for the testing of vaccine candidates where alternative models are not available. Characterisation of the immunogenicity of antigenic targets in appropriate animal or alternative models and in pre-clinical tests. Inclusion, if possible, of proof-of-concept studies in humans of the vaccine candidate
Procedure and application process: For more information, click here.
HORIZON-HLTH-2023-DISEASE-05-08
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
• The scientific and clinical communities, including health care providers and payers, as well as regulators, health systems and patients benefit from innovative diagnostic solutions that are better suited to tackle cross-border health threats.
• The scientific and clinical communities have access to novel and improved methodologies for detection of pathogens with pandemic potential in humans and for timely discovery of other health threats, such as chemical, radiological and nuclear threats, including considerations on detection in animals and environmental conditions (One Health approach).
• A diverse and robust pipeline of in vitro diagnostics is available, increasing options for clinical deployment in case of an epidemic or pandemic.
Funding Name: Pandemic preparedness and response: In vitro diagnostic devices to tackle cross-border health threats (Innovation Action call)
Funding Organization: European Commission
Amount of funding per project: € 5-7 (Total budget €40M)
Funding versus total project costs: 70% for SMEs and 100% funding for non-profit entities
Close date: Opening January 12, 2023 – Closing April 13, 2023
Duration of eligible projects: Unspecified
Evaluation results expected: Typically 5 months
Scope: Proposals should develop and advance on new in vitro diagnostics relevant for detecting and characterising cross-border health threats and develop novel approaches to the development of medical countermeasures targeting threats identified by HERA. Proposals should cover pathogens with pandemic potential in humans or other health threats, such as chemical, radiological and nuclear threats for which there are no existing diagnostics or where clinical practice could benefit from innovation. Emphasis should be put on the development of new diagnostics, innovative catch-all methodologies, or on the improvement of existing health technologies advancing diagnostics and characterisation of health threats, applying the One Health approach when relevant.
Eligibility criteria:
Proposals should include a clear regulatory path to market in order to ensure future compliance with the legal requirements. Proposals should address several of the following areas: Proof-of-concept/early studies linked e.g. to performance evaluation of new diagnostics that facilitate screening, detection of the presence or exposure to a cross-border health threat or determination of infectious/disease status through human samples, included but not limited to the list of high impact health threats identified by HERA, as well chemical, radiological and nuclear threats for which there is a lack of in vitro diagnostics or existing diagnostics have a sub-optimal performance. Data-driven diagnostic and prognostic platforms with AI and other advanced data analytics functionalities, adaptable to respond to new and multiple pathogens/threats, e.g. covering prototype viruses. Innovative systems linked to high sensitivity/specificity profiles adaptable for broader use should be considered, such as portable, faster, more compact or accurate devices and technologies, including the possibility to develop point of care or self-tests. Innovative diagnostics sampling methods or samples bringing a significant improvement, such as less invasive sampling methods.
Procedure and application process: For more information, click here.
Long-term engaging institutions and programmes
barda
Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile. BARDA will draw on its extensive experience of successfully advancing promising medical countermeasures through late-stage development and provide $30 million during the project’s first year and up to $250 million during the five-year program.
Funding Name: Broad Agency Announcement (BAA)
Funding Organization: BARDA
Amount of funding per project: € No maximum
Funding versus total project costs: 100%
Close date: None
Duration of eligible projects: Up to 5 years
Evaluation results expected: Unspecified
Scope: Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.
COVID-19 response related Areas of Interest includes:
• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies
Eligibility:
Applicants can be from any country.
Applicants may include single entities or teams from private sector organizations, government laboratories, and academic institutions.
Procedure and application process: For more information, click here.
carb-x
Co-founded by BARDA, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership funding new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections. CARB-X’s Global Accelerator Network provides business, scientific, and technical expertise to CARB-X-funded product developers to support their antibacterial research projects focused on the most serious drug-resistant bacteria identified by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).
Funding Name: CARB-X
Funding Organization: CARB-X
Amount of funding per project: Total budget €480M
Funding versus total project costs: Unspecified
Close date: Unspecified
Duration of eligible projects: Unspecified
Evaluation results expected: Unspecified
Scope: The scope of CARB-X is to target drug-resistant bacteria highlighted on the ‘Antibiotic Resistant Threats in the United States’ report published by the CDC in 2013 or the Priority Bacterial Pathogens list published by the WHO in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list.
Eligibility:
There are currently no new funding rounds scheduled at the moment.
Procedure and application process: For more information, click here.
InnovFin Infectious Diseases
The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between €7.5 million and €75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.
Funding Name: InnovFin Infectious Disease
Funding Organization: European Investment Bank
Amount of funding per project: €7.5-75M
Funding versus total project costs: Unspecified
Close date: Unspecified
Duration of eligible projects: Unspecified
Evaluation results expected: Unspecified
Scope: Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.
The product is being made available directly through the European Investment Bank.In addition, it should have passed successfully through the pre-clinical stage or through the proof-of-concept stage (in the case of medical and diagnostic devices). Funding can be invested in research infrastructure that provides facilities, resources and related services for use by the scientific community to conduct top-level research in the ID field.
Eligibility:
To be eligible for InnovFin Infectious Diseases Finance Facility (IDFF) funding, counterparties must comply with the following criteria:
The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV). Promoters, sponsors and/or operators must be willing to substantially co-fund the project.
Procedure and application process: For more information, click here.